These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

174 related articles for article (PubMed ID: 25980912)

  • 1. Design of selective PI3Kα inhibitors starting from a promiscuous pan kinase scaffold.
    Barlaam B; Cosulich S; Fitzek M; Green S; Harris CS; Hudson K; Lambert-van der Brempt C; Ouvry G; Page K; Ruston L; Ward L; Delouvrié B
    Bioorg Med Chem Lett; 2015 Jul; 25(13):2679-85. PubMed ID: 25980912
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Design, Synthesis and Biological Evaluation of Novel Benzothiazole Derivatives as Selective PI3Kβ Inhibitors.
    Cao S; Cao R; Liu X; Luo X; Zhong W
    Molecules; 2016 Jul; 21(7):. PubMed ID: 27384552
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Design and synthesis of imidazopyridine analogues as inhibitors of phosphoinositide 3-kinase signaling and angiogenesis.
    Kim O; Jeong Y; Lee H; Hong SS; Hong S
    J Med Chem; 2011 Apr; 54(7):2455-66. PubMed ID: 21388141
    [TBL] [Abstract][Full Text] [Related]  

  • 4. Combining properties of different classes of PI3Kα inhibitors to understand the molecular features that confer selectivity.
    Gong GQ; Kendall JD; Dickson JMJ; Rewcastle GW; Buchanan CM; Denny WA; Shepherd PR; Flanagan JU
    Biochem J; 2017 Jun; 474(13):2261-2276. PubMed ID: 28526744
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Discovery of novel 2-piperidinol-3-(arylsulfonyl)quinoxalines as phosphoinositide 3-kinase α (PI3Kα) inhibitors.
    Wu P; Su Y; Liu X; Yang B; He Q; Hu Y
    Bioorg Med Chem; 2012 May; 20(9):2837-44. PubMed ID: 22480851
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Identification of allosteric binding sites for PI3Kα oncogenic mutant specific inhibitor design.
    Miller MS; Maheshwari S; McRobb FM; Kinzler KW; Amzel LM; Vogelstein B; Gabelli SB
    Bioorg Med Chem; 2017 Feb; 25(4):1481-1486. PubMed ID: 28129991
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Rationally Designed PI3Kα Mutants to Mimic ATR and Their Use to Understand Binding Specificity of ATR Inhibitors.
    Lu Y; Knapp M; Crawford K; Warne R; Elling R; Yan K; Doyle M; Pardee G; Zhang L; Ma S; Mamo M; Ornelas E; Pan Y; Bussiere D; Jansen J; Zaror I; Lai A; Barsanti P; Sim J
    J Mol Biol; 2017 Jun; 429(11):1684-1704. PubMed ID: 28433539
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Design, synthesis and biological evaluation of novel condensed pyrrolo[1,2-c]pyrimidines featuring morpholine moiety as PI3Kα inhibitors.
    Ibrahim MA; Abou-Seri SM; Hanna MM; Abdalla MM; El Sayed NA
    Eur J Med Chem; 2015 Jun; 99():1-13. PubMed ID: 26037808
    [TBL] [Abstract][Full Text] [Related]  

  • 9. A novel approach for the development of selective Cdk4 inhibitors: library design based on locations of Cdk4 specific amino acid residues.
    Honma T; Yoshizumi T; Hashimoto N; Hayashi K; Kawanishi N; Fukasawa K; Takaki T; Ikeura C; Ikuta M; Suzuki-Takahashi I; Hayama T; Nishimura S; Morishima H
    J Med Chem; 2001 Dec; 44(26):4628-40. PubMed ID: 11741480
    [TBL] [Abstract][Full Text] [Related]  

  • 10. PF-04859989 as a template for structure-based drug design: identification of new pyrazole series of irreversible KAT II inhibitors with improved lipophilic efficiency.
    Dounay AB; Anderson M; Bechle BM; Evrard E; Gan X; Kim JY; McAllister LA; Pandit J; Rong S; Salafia MA; Tuttle JB; Zawadzke LE; Verhoest PR
    Bioorg Med Chem Lett; 2013 Apr; 23(7):1961-6. PubMed ID: 23466229
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Structure-based design and subsequent optimization of 2-tolyl-(1,2,3-triazol-1-yl-4-carboxamide) inhibitors of p38 MAP kinase.
    Cogan DA; Aungst R; Breinlinger EC; Fadra T; Goldberg DR; Hao MH; Kroe R; Moss N; Pargellis C; Qian KC; Swinamer AD
    Bioorg Med Chem Lett; 2008 Jun; 18(11):3251-5. PubMed ID: 18462940
    [TBL] [Abstract][Full Text] [Related]  

  • 12. Structure-based virtual screening approach to the discovery of phosphoinositide 3-kinase alpha inhibitors.
    Park H; Choi H; Hong S; Kim D; Oh DS; Hong S
    Bioorg Med Chem Lett; 2011 Apr; 21(7):2021-4. PubMed ID: 21354792
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Discovery and synthesis of a novel series of potent, selective inhibitors of the PI3Kα: 2-alkyl-chromeno[4,3-c]pyrazol-4(2H)-one derivatives.
    Yin Y; Wu X; Han HW; Sha S; Wang SF; Qiao F; Lu AM; Lv PC; Zhu HL
    Org Biomol Chem; 2014 Dec; 12(45):9157-65. PubMed ID: 25296388
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Discovery of triazole aminopyrazines as a highly potent and selective series of PI3Kδ inhibitors.
    Terstiege I; Perry M; Petersen J; Tyrchan C; Svensson T; Lindmark H; Öster L
    Bioorg Med Chem Lett; 2017 Feb; 27(3):679-687. PubMed ID: 28017532
    [TBL] [Abstract][Full Text] [Related]  

  • 15. The Guareschi Pyridine Scaffold as a Valuable Platform for the Identification of Selective PI3K Inhibitors.
    Galli U; Ciraolo E; Massarotti A; Margaria JP; Sorba G; Hirsch E; Tron GC
    Molecules; 2015 Sep; 20(9):17275-87. PubMed ID: 26393561
    [TBL] [Abstract][Full Text] [Related]  

  • 16. [Study on derivatives of 5-amino-4-acylamino-1H-pyrazole as inhibitors of furin].
    Kibirev VK; Osadchuk TV; Vadziuk OB; Shablykin OV; Kozachenko AP; Chumachenko SA; Popil'nichenko SV; Brovarets VS
    Ukr Biokhim Zh (1999); 2011; 83(1):30-7. PubMed ID: 21800646
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Potent and selective pyrazolo[1,5-a]pyrimidine based inhibitors of B-Raf(V600E) kinase with favorable physicochemical and pharmacokinetic properties.
    Ren L; Laird ER; Buckmelter AJ; Dinkel V; Gloor SL; Grina J; Newhouse B; Rasor K; Hastings G; Gradl SN; Rudolph J
    Bioorg Med Chem Lett; 2012 Jan; 22(2):1165-8. PubMed ID: 22196124
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Structure guided optimization of a fragment hit to imidazopyridine inhibitors of PI3K.
    Pecchi S; Ni ZJ; Han W; Smith A; Lan J; Burger M; Merritt H; Wiesmann M; Chan J; Kaufman S; Knapp MS; Janssen J; Huh K; Voliva CF
    Bioorg Med Chem Lett; 2013 Aug; 23(16):4652-6. PubMed ID: 23820386
    [TBL] [Abstract][Full Text] [Related]  

  • 19. Non-oxime pyrazole based inhibitors of B-Raf kinase.
    Newhouse BJ; Hansen JD; Grina J; Welch M; Topalov G; Littman N; Callejo M; Martinson M; Galbraith S; Laird ER; Brandhuber BJ; Vigers G; Morales T; Woessner R; Randolph N; Lyssikatos J; Olivero A
    Bioorg Med Chem Lett; 2011 Jun; 21(11):3488-92. PubMed ID: 21536432
    [TBL] [Abstract][Full Text] [Related]  

  • 20. Optimization of pyrazole inhibitors of Coactivator Associated Arginine Methyltransferase 1 (CARM1).
    Huynh T; Chen Z; Pang S; Geng J; Bandiera T; Bindi S; Vianello P; Roletto F; Thieffine S; Galvani A; Vaccaro W; Poss MA; Trainor GL; Lorenzi MV; Gottardis M; Jayaraman L; Purandare AV
    Bioorg Med Chem Lett; 2009 Jun; 19(11):2924-7. PubMed ID: 19419866
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 9.